<DOC>
	<DOCNO>NCT01351610</DOCNO>
	<brief_summary>MSC_Apceth GMP-manufactured , autologous ex-vivo expand non-hemapoietic bone-marrow derived stem cell treatment Critical Limb Ischemia</brief_summary>
	<brief_title>Tolerability Efficacy Intravenous Infusion Autologous MSC_Apceth Treatment Critical Limb Ischemia</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<criteria>1 . Patients peripheral arterial occlusive disease ( symptomatic PAOD ) , diagnosis CLI define persistent , recur ischemic rest pain least 2 week , and/or ulceration gangrene foot toe , ABPI &lt; /= 0.5 , 2 . Patients stag ≥III accord Fontaine ≥4 accord Rutherford category , 3 . Patients fulfil criterion invasive revascularisation procedure ( PTA ) discretion investigator , 4 . Patients without major amputation low extremity within period 6 month inclusion opinion investigator , 1 . Patients wound severity great grade 2 Wagner Scale , 2 . Patients lifethreatening ventricular arrhythmia , 3 . Patients unstable angina pectoris , 4 . Patients severe congestive heart failure ( i.e . NYHA Stage IV ) , 5 . Patients uncontrolled hypertension ( define diastolic blood pressure &gt; 110 mmHg systolic blood pressure &gt; 180 mmHg screening ) , 6 . Patients uncontrolled diabetes mellitus ( HbA1c &gt; 9 % ) , 7 . Patients history malignant tumour anamnesis currently tumour treatment , 8 . Patients unsuitable MSC stem cell therapy opinion investigator ,</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Critical Limb Ischemia</keyword>
	<keyword>Peripheral Arterial Occlusive Disease</keyword>
	<keyword>Peripheral Artery Disease</keyword>
	<keyword>Peripheral Vascular Disease</keyword>
	<keyword>Stem Cell Therapy</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
</DOC>